A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin

por Han, Nanumi, Wada, Haruka, Kobayashi, Takuto, Otsuka, Ryo, Seino, Ken-Ichiro
Publicado 2023

An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance

por Han, Nanumi, Jang, Hye Yoon, Hama, Naoki, Kobayashi, Takuto, Otsuka, Ryo, Wada, Haruka, Seino, Ken-ichiro
Publicado 2021

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

por Han, Nanumi, Baghdadi, Muhammad, Ishikawa, Kozo, Endo, Hiraku, Kobayashi, Takuto, Wada, Haruka, Imafuku, Keisuke, Hata, Hiroo, Seino, Ken-ichiro
Publicado 2018

Interleukin-34 cancels anti-tumor immunity by PARP inhibitor

por Nakamura, Takayoshi, Kajihara, Nabeel, Hama, Naoki, Kobayashi, Takuto, Otsuka, Ryo, Han, Nanumi, Wada, Haruka, Hasegawa, Yoshinori, Suzuki, Nao, Seino, Ken-ichiro
Publicado 2022

Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells

por Han, Nanumi, Anwar, Delnur, Hama, Naoki, Kobayashi, Takuto, Suzuki, Hidefumi, Takahashi, Hidehisa, Wada, Haruka, Otsuka, Ryo, Baghdadi, Muhammad, Seino, Ken-ichiro
Publicado 2020

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade

por Hama, Naoki, Kobayashi, Takuto, Han, Nanumi, Kitagawa, Fumihito, Kajihara, Nabeel, Otsuka, Ryo, Wada, Haruka, Lee, Hee-kyung, Rhee, Hwanseok, Hasegawa, Yoshinori, Yagita, Hideo, Baghdadi, Muhammad, Seino, Ken-ichiro
Publicado 2020

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade

por Hama, Naoki, Kobayashi, Takuto, Han, Nanumi, Kitagawa, Fumihito, Kajihara, Nabeel, Otsuka, Ryo, Wada, Haruka, Lee, Hee-kyung, Rhee, Hwanseok, Hasegawa, Yoshinori, Yagita, Hideo, Baghdadi, Muhammad, Seino, Ken-ichiro
Publicado 2022